Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 21,004 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ONE Clear all
Terminated No phase listed Observational Results available

Safety and Performance Study of the Siello S Pacing Lead

NCT01791127
View directory record Official record
Conditions
Safety and Effectiveness of the Siello S Lead
Interventions
market-released BIOTRONIK pacemaker system including one or two Siello S leads.
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
53
States / cities
La Jolla, California • La Mesa, California • New Haven, Connecticut + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A School Health Center Intervention to Increase Adolescent Vaccination

NCT01595542
View directory record Official record
Conditions
Immunization Program, School Health Services, HPV Vaccines
Interventions
Modified Vaccine Consent Form
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
3,417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

NCT01283594
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 30, 2026, 2:32 PM EDT
Recruiting Not applicable Interventional

Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors

NCT07174661
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Malignant Brain Neoplasm, Recurrent Advanced Malignant Solid Neoplasm
Interventions
Advance Care Planning, Educational Intervention, Electronic Health Record Review, Survey Administration
Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 39 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Determine the Effectiveness of a Self-regulation Program to Treat Pediatric Obesity

NCT01442142
View directory record Official record
Conditions
Obesity
Interventions
CAAT: Appetite Awareness, CRST: Volcravo, Combined CAAT and CRST program
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 12 Years
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

NCT02605954
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 30, 2026, 2:32 PM EDT
Completed No phase listed Observational

A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients

NCT07644351
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 30, 2026, 2:32 PM EDT
Active, not recruiting No phase listed Observational

Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study

NCT02754037
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), PET Explorer
Radiation · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Understanding Visual Confusion Using Stereoscopic Displays

NCT04957745
View directory record Official record
Conditions
Diplopia, Binocular Vision Suppression, Binocular; Fusion, With Defective Stereopsis, Monocular Diplopia
Interventions
Binocular visual confusion (unilateral opaque), Unilateral monocular visual confusion (unilateral see-through), Bilateral monocular visual confusion (bilateral see-through)
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
14 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 3 Interventional

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

NCT00069745
View directory record Official record
Conditions
Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
Satraplatin, Prednisone
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
105
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 30, 2026, 2:32 PM EDT
Recruiting Not applicable Interventional

At-Home Genital Nerve Stimulation for SCI Bowel

NCT06836739
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Genital nerve stimulation
Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Results available

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

NCT03542175
View directory record Official record
Conditions
Breast Cancer
Interventions
Rucaparib, Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Stress Management (CBSM) & Prostate Cancer

NCT05486754
View directory record Official record
Conditions
Stress
Interventions
Cognitive behavioral stress management, Psychoeducational Control
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Amlodipine Tablets Under Fasting Conditions

NCT00775905
View directory record Official record
Conditions
Healthy
Interventions
amlodipine 10 mg tablet
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 30, 2026, 2:32 PM EDT
Active, not recruiting Not applicable Interventional

The Synergy Disc To Anterior Cervical Discectomy and Fusion

NCT04469231
View directory record Official record
Conditions
Cervical Degenerative Disc Disease
Interventions
Anterior Cervical Discectomy & Fusion
Device
Lead sponsor
Synergy Spine Solutions
Industry
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study Between Colchicine and Cyclosporine

NCT00983931
View directory record Official record
Conditions
Pharmacokinetics, Healthy
Interventions
Colchicine, Cyclosporine
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

NCT00667745
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Optimized Treatment (OPT)
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 80 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Stanford, California • Boston, Massachusetts • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Abbott Laboratories Alinity s Blood Screening Assays - Clinical Evaluation Protocol

NCT03285295
View directory record Official record
Conditions
Healthy
Interventions
Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay, Alinity s HTLV I/II Assay, Alinity s Anti-HCV Assay, Alinity s HIV Ag/Ab Combo Assay, Alinity s Anti-HBc Assay, Alinity s Chagas Assay
Device
Lead sponsor
Abbott Diagnostics Division
Industry
Eligibility
16 Years and older
Enrollment
106,881 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
5
States / cities
Boca Raton, Florida • St Louis, Missouri • Knoxville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Nicotine on Brain Reward Pathways

NCT02346539
View directory record Official record
Conditions
Depressive Disorder
Interventions
Nicotine polacrilex
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Not applicable Interventional

Adapting and Testing a Novel Self-Compassion Intervention to Reduce Lung Cancer Stigma

NCT06191939
View directory record Official record
Conditions
Lung Cancer
Interventions
Mindful Self-Compassion for Lung Cancer (MSC-LC), Enhanced standard of care with waitlist
Behavioral · Other
Lead sponsor
Loyola Marymount University
Other
Eligibility
18 Years to 100 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver

NCT00149396
View directory record Official record
Conditions
Colorectal Cancer, Liver Neoplasms
Interventions
NV1020
Drug
Lead sponsor
MediGene
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
San Diego, California • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

NCT02860546
View directory record Official record
Conditions
Refractory Metastatic Colorectal Cancer
Interventions
TAS-102, nivolumab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Not applicable Interventional Results available

Validation of Indiana's Early Evaluation Hub System

NCT06586788
View directory record Official record
Conditions
Autism
Interventions
Eyelink Portable Duo, Integrated PCP Diagnosis and Eye-tracking Biomarker
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
14 Months to 48 Months
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Anderson, Indiana • Batesville, Indiana • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02009488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Diego, La Jolla, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 30, 2026, 2:32 PM EDT